6/2/2010 8:33:28 AM
SEATTLE, June 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced it will present a corporate update at the 9th Annual Needham Healthcare Conference to be held at the New York Palace Hotel, 455 Madison Avenue in New York City. Michelle Burris, senior vice president and chief operating officer, and John Bencich, vice president and chief financial officer, are scheduled to present on Thursday, June 10 at 2:40 pm ET in the Henry conference room (5th floor). The presentation will be available via audio webcast at: http://www.wsw.com/webcast/needham38/trbn/.
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the Company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules as well as simultaneously neutralizing soluble ligands. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.
SOURCE Trubion Pharmaceuticals, Inc.